Changchun High-tech: The company never uses single-market rumors as a basis for valuation.

On March 6, Changchun High-tech said in response to investors’ questions on the interactive platform that the company never treats a single market rumor as its value orientation. It always stays focused on R&D innovation and clinical value, continuously remains patient-centered and innovation-driven, and keeps strengthening its core competitiveness. For its major products, the company will continue to make efforts to leverage advantages such as its brand, distribution channels, and quality, and, based on the results of medical insurance negotiations, will continue to promote the sales and marketing of related products. Meanwhile, in recent years, the company has already been actively advancing diversified transformation and upgrading. The foundation laid in the earlier stages of growth hormone R&D and sales promotion will also continue to empower new pipelines, helping the company continuously form a virtuous cycle of “shared advantages and resource reuse.” For details on the specific new products and products under development, please refer to the company’s related announcements.